Literature DB >> 11896090

Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!

Gavin M Marx, Christopher B Steer, Peter Harper, Nick Pavlakis, Olivier Rixe, David Khayat.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896090     DOI: 10.1200/JCO.2002.20.6.1446

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.

Authors:  Catherine Delbaldo; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal:  Ther Adv Med Oncol       Date:  2012-01       Impact factor: 8.168

2.  A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.

Authors:  I Diaz-Padilla; L L Siu; M San Pedro-Salcedo; A R A Razak; A D Colevas; F A Shepherd; N B Leighl; J W Neal; A Thibault; L Liu; J Lisano; B Gao; E B Lawson; H A Wakelee
Journal:  Br J Cancer       Date:  2012-07-17       Impact factor: 7.640

3.  Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin.

Authors:  Rui Z Bai; Yang Wu; Quan Liu; Ke Xie; Yu Q Wei; Yong S Wang; Kang Liu; Yan Luo; Jing M Su; Bing Hu; Ji Y Liu; Qiu Li; Ting Niu; Zhi W Zhao; Li Yang
Journal:  J Exp Clin Cancer Res       Date:  2009-03-05

4.  Cancer-associated thrombosis: prevention and treatment.

Authors:  K M J Brose; A Y Y Lee
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

Review 5.  Tissue factor, angiogenesis and tumour progression.

Authors:  Joanne E Bluff; Nicola J Brown; Malcolm W R Reed; Carolyn A Staton
Journal:  Breast Cancer Res       Date:  2008-03-17       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.